LakeShore Biopharma Co., Ltd

LakeShore Biopharma submits BLA to DRAP for PIKA Rabies Vaccine, supported by Phase III trial data showing accelerated protection and higher seroconversion rate, aiming to shorten rabies vaccine regimens to one week.

LakeShore Biopharma submits Biologics License Application to Pakistan's Drug Regulatory Authority for its PIKA rabies vaccine, supported by Phase 3 trial results showing accelerated protection in 7 days vs. conventional 3-4 week regimens, with superior immunogenicity and safety in 4,500 participants from the Philippines and Pakistan.

LakeShore Biopharma granted Phase III clinical trial approval by NMPA in China to explore simplified four-dose regimens for its YSJA rabies vaccine, aiming to improve patient adherence and reduce financial burden. The trial will evaluate immunogenicity and safety of the Zagreb (2-1-1) and Modified Essen (1-1-1-1) regimens compared to the Essen (1-1-1-1-1) regimen, starting December 2024.

LakeShore Biopharma's YSJA rabies vaccine receives NMPA approval for Phase III trial in China to test simplified four-dose regimens, aiming to enhance patient adherence and reduce financial burden while maintaining immunogenicity.

LakeShore Biopharma granted Phase III trial approval by NMPA in China to explore simplified four-dose regimens for its YSJA rabies vaccine, aiming to improve patient adherence and reduce financial burden.

LakeShore Biopharma's YSJA rabies vaccine Phase III trial approved by China's NMPA to test simplified four-dose regimens for immunogenicity and safety, aiming to enhance patient adherence and reduce financial burden. Trial to start Dec 2024, comparing Zagreb and Modified Essen regimens to existing Essen regimen.